Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases
August 01 2022 - 7:05PM
Sosei Group Corporation (“the Company”; TSE: 4565) and AbbVie
(NYSE: ABBV), a research-based global biopharmaceutical company,
announce they have entered a new drug discovery collaboration and
option-to-license agreement to discover, develop and commercialize
small molecules that modulate novel G protein-coupled receptor
(GPCR) targets associated with neurological disease.
The new agreement will leverage Sosei Heptares’
StaR® technology and structure-based drug design (SBDD) platform
and AbbVie’s extensive neuroscience and disease area expertise. The
agreement expands the breadth of the ongoing collaboration between
Sosei Heptares and AbbVie, building on the first multi-target
discovery agreement signed between the companies in June 2020,
which is focused on the inflammatory and autoimmune disease
areas.
Under the terms of the new agreement, Sosei
Heptares will conduct and fund R&D activities through the
completion of Investigational New Drug (IND)-enabling studies.
AbbVie has the exclusive option to license up to three programs at
this stage and will have responsibility for clinical, regulatory
and commercial development thereafter. Sosei Heptares receives an
upfront payment of US$40 million on signing and is eligible to
receive up to US$40 million in near-term research milestone
payments expected over the next three years, as well as further
potential option, development and commercial milestones totalling
up to US$1.2 billion, plus tiered royalties on global sales.
Matt Barnes, Head of UK Research &
Development, Sosei Heptares said: “We are delighted to
enter this new multi-target discovery collaboration with AbbVie in
the neuroscience area, a therapeutic area in which we share deep
and complementary experience and expertise. We have established a
highly productive working relationship with our counterparts at
AbbVie over the past two years through our initial collaboration
and are very pleased with how this is progressing. We believe this
strong foundation will enable us to get off to a quick start as we
tackle the novel and challenging neurology targets under this new
agreement.”
About Sosei Heptares
We are an international biopharmaceutical group
focused on the discovery and early development of new medicines
originating from our proprietary GPCR-targeted StaR® technology and
structure-based drug design platform capabilities. We are advancing
a broad and deep pipeline of novel medicines across multiple
therapeutic areas, including neurology, immunology,
gastroenterology and inflammatory diseases.
We have established partnerships with some of
the world’s leading pharmaceutical companies and multiple emerging
technology companies, including AbbVie, AstraZeneca, Biohaven,
Genentech (Roche), GSK, Neurocrine Biosciences, Novartis, Pfizer,
Takeda and Verily. Sosei Heptares is headquartered in Tokyo, Japan
with corporate and R&D facilities in Cambridge, UK.
“Sosei Heptares” is the corporate brand and
trademark of Sosei Group Corporation, which is listed on the Tokyo
Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR®
are trademarks of Sosei Group companies.
For more information, please visit
https://soseiheptares.com/LinkedIn: @soseiheptaresco | Twitter:
@soseiheptaresco | YouTube: @soseiheptaresco
Enquiries: Sosei
Heptares – Media and Investor
RelationsHironoshin Nomura, Chief Financial Officer
Shinichiro Nishishita, VP Investor Relations, Head of Regulatory
DisclosuresCandelle Chong, SVP Investor Relations and Corporate
StrategyJapan: +81 (0)3 5210 3399 | United
Kingdom: +44 (0)1223 949390 | IR@SoseiHeptares.com
MEDiSTRAVA Consulting (for International
Media)Mark Swallow, Frazer Hall, Eleanor Perkin+44 (0)203
928 6900| SoseiHeptares@medistrava.com
Sosei Heptares Forward-looking
statementsThis press release contains forward-looking
statements, including statements about the discovery, development
and commercialization of products. Various risks may cause Sosei
Group Corporation’s actual results to differ materially from those
expressed or implied by the forward-looking statements, including:
adverse results in clinical development programs; failure to obtain
patent protection for inventions; commercial limitations imposed by
patents owned or controlled by third parties; dependence upon
strategic alliance partners to develop and commercialize products
and services; difficulties or delays in obtaining regulatory
approvals to market products and services resulting from
development efforts; the requirement for substantial funding to
conduct research and development and to expand commercialization
activities; and product initiatives by competitors. As a result of
these factors, prospective investors are cautioned not to rely on
any forward-looking statements. We disclaim any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2024 to Aug 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Aug 2023 to Aug 2024